The IBD-BIOM Consortium Partners

The nine partner organisations in the programme include specialist scientific and medical laboratories across Europe and the US. Here are brief summaries of each of the partner organisations and their roles in the IBD-BIOM programme

Partner 1: University of Edinburgh, Scotland, UK (Short Name: UEDIN)

The Edinburgh group are the main administrative and scientific coordinators for the IBD-BIOM programme.

The group's scientific work is lead by Prof. Jack Satsangi. Jack has a strong background in basic, clinical and translational IBD research, especially in national and international gene discovery programmes. He is a co-Principal Investigator of the UK IBD Genetics Consortium, and was a founder member of the international consortia in both adult-onset and childhood onset IBD. Jack is also the co-Chairman and senior author of the Montreal working party which re-classified the IBD phenotype, is the author of the 2010 UK IBD Research agenda, and of the 2011 IBD guidelines on behalf of the British Society for Gastroenterology. Jack’s research interests include the integration of genomic, microbiome, and epigenetic data in translational research. Jack is the Principal Investigator of the Edinburgh database and DNA bank involving several thousand IBD patients.

The group includes medical epidemiologists Prof Harry Campbell and Dr Igor Rudan who have published >40 genome-wide association (GWA) studies including those on ‘omics’ traits (such as plasma and IgG N-glycosylation and a large number of lipidomics species), immunological and biochemical traits. They also have established collaborations with several of the other IBD-BIOM partners and have joint glycomics diagnostic marker patent with Genos (IBD-BIOM partner 2).

PublicationsThe group’s scientific publications over the past five years include more than twenty in Nature and Nature Genetics.

Partner 2: Genos Ltd, Zagreb, Croatia

Genos Ltd is a research intensive Croatian SME and and one of the global leaders in high throughput glycomic analysis. The group is lead by Prof Gordan Lauc who performed the first large scale glycomics analysis of the human plasma and IgG glycomes and the first GWAS-glycomics on human plasma. Genos will lead the plasma and IgG glycome analysis for the consortium.

Publications: Mol Cell Proteomics 10: M111.010090, 2011; Mol Cell Proteomics 10: M110 004200, 2011; Mol Biosyst, 7:1852; PLoS Genetics 6:e1001256, 2010; Glycobiology 20:959, 2010; Glycobiology 20:970; J. Proteome Res. 8:694, 2009.

Partner 3: Ludger Ltd, Oxford, UK

Ludger Ltd is a life sciences company based in Oxford UK specialising in the development of analytical glycoprofiling technology for biopharmaceutical realisation. The group leader, Dr Daryl Fernandes, was one of the pioneers of glycan analysis in Europe. The company will be responsible for the development of methods for high throughout quantitative analysis of O-glyosylation as well as formal validation of technologies developed within the consortium. Ludger will also oversee dissemination and exploitation of the results of the IBD-BIOM consortium's research.

Publications: Biopharm Int, Jan 2011; Biopharmaceutical Production Technology, Wiley-VCH Verlag, 2012

Partner 4: IP Research Consulting SAS, Paris, France

IP Research Consulting SAS, a research intensive SME based in the Paris region since 2005, offers proteomics based research services in biomarker discovery under the commercial name of Photeomix Protein Discovery ( Photeomix specialises in the discovery and validation of biomarkers based on post-translational protein modification activities. The team led by Dr Iain Pemberton recently launched its proprietary Activomics® platform which integrares multiplexed protein modification enzyme activities with mass spectrometry to provide a comprehensive analysis of post-translational modification activities linked to disease.

Publications: Arch Physiol Biochem 116:163, 2010; Methods Mol Biol. 641:27, 2010 J Proteome Res 9:3842, 2010; Arch Physiol Biochem 115:267, 2009.

Partner 5: University Hospital Careggi, Florence, Italy

Dr Vito Annese is the Director of Gasteroenterology at the hospital and is an expert in clinical treatment of ulcerative colitis and Crohn's disease. His research activities include contributions to the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) and he is a member of the European Crohn's and Colitis Organisation.

Publications: PLoS One. 8:e62144, 2013; Nature 491:119-124, 2012.

Partner 6: Leiden University Medical Center, Netherlands

The Glycomics and Glycoproteomics group at the LUMC lead by Dr. Manfred Wuhrer has a strong background in the development of mass spectrometry (MS) -focused glycoanalytical techniques and their application in high-throughput clinical glycomics. They will work together with Ludger characterisation of the glycome by MS.

Publications: Mol Cell Proteomics M110.004655, 2011; Mol Cell Proteomics M110.005710, 2011; Anal Chem 83:2492, 2011; J Proteome Res 9:6655, 2010; Anal Chem 82:1073, 2010.

Partner 7: University of Zagreb, Croatia

The epigenetics group led by Prof Vlatka Zoldoš at the University of Zagreb performed the first studies of the epigenetic regulation of the human glycome and will bring this technology and experience to the consortium.

Publications: Hum Mol Genetics, doi: 10.1093/hmg/ddr414, 2011; Clin Epigenetics 2:425, 2011; Mol Biosystems 6:2373, 2010; PLOS Genetics 6:e1001256, 2010; Biomol Concepts 1:253, 2010.

Partner 8: Max Planck Institute, Berlin, Germany

Dr Daniel Kolarich has comprehensive track-record in developing novel approaches for glycoproteomics research to study the role of glycoproteins and protein glycosylation in cell-cell interaction and innate immunity. He will target the bowel membrane glycoproteome representing the first line of immune defense with the bowel microbiome and thus likely key players in IBDs.

Publications: Mol Cell Proteomics. 10:M111.009100, 2011; Mol Cell Proteomics. 10:M110.006833, 2011; J Biol Chem. 286:5977-84, 2011; Anal Chem. 82:3500-9, 2010; Mol Cell Proteomics. 9:719-27, 2010; J Proteome Res. 9:1063-75, 2010; FEBS J. 277:81-94, 2010; Proteomics. 8:254-63, 2008.

Partner 9: Cedars Sinai Mecical Center, Los Angeles, USA

The group at CS-MC led by Dr Dermot McGovern and Dr Jerrome Rotter is one of global leaders in IBD. In addition to their extensive experience, they will enrich the consortium by bringing 3000 IBD cases with genome-wide association data, immunochip data, ‘exome’ chip, immortalised cell lines, and serum available all of whom have been meticulously phenotyped.

Publications: Nat Genet. 2011;43:246-52; Nat Genet. 2010;42:1118-25; IBD Journal 2010;16:1830-40; Hum Mol Gen.; 19:3468-76. Nat Genet. 2010;42(4):332-7. Nat Genet. 2009;41(12):1335-40; Immunogenetics. 2009;61(10):663-71. Nat Genet 2009; 41(2):216-20.

Partner 10: Maastricht University Medical Centre, Netherlands

Dr Marieke Pierik is Head of the IBD clinic at MUMC. She is also the founder of the biobank project of the population based IBD South-Limburg (IBDSL) cohort. The group also includes the expertise of Dr Daisy Jonkers who is heading the research laboratory of Gastroenterology. The MUMC will contribute to the recruitment of newly diagnosed IBD patients.

Publications: PLoS One. 2014;7:9(3); Eur J Gastroenterol Hepatol. 2014;26(8):902-9; Inflamm Bowel Dis. 2013;19(10):2125-31; Inflamm Bowel Dis. 2010;16(12):2137-47.